FDA Accepts Collaborative IND Application for BIVV003 to Treat Sickle Cell Disease
News
The U.S. Food and Drug Administration recently accepted an investigational new drug (IND) application submitted by Bioverativ and Sangamo Therapeutics for BIVV003, a gene-edited cell therapy candidate for the treatment ... Read more